Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin

J Breast Cancer. 2015 Dec;18(4):400-3. doi: 10.4048/jbc.2015.18.4.400. Epub 2015 Dec 23.

Abstract

Adenomyoepithelioma (AME) of the breast is an uncommon tumor characterized by its dual differentiation into luminal cells and myoepithelial cells. In most cases these tumors have a benign clinical course, but distant metastases have been reported. We present the case of a 51-year-old woman diagnosed with malignant AME. The patient underwent a right modified radical mastectomy, and pathological examination confirmed the diagnosis of malignant AME. Ten months after the operation, multiple hepatic, pleural, and abdominal wall metastases were detected. A number of palliative chemotherapeutic agents were tried, including anthracycline and taxanes. However, the disease continued to progress, and superior vena cava syndrome developed as a result of direct tumor invasion. The patient received salvage eribulin monotherapy. After two cycles of this treatment, her clinical symptoms were ameliorated, and a computed tomography scan showed a partial response. Eribulin chemotherapy was thus effective in treating malignant AME in this case.

Keywords: Breast; Eribulin; Malignant adenomyoepithelioma; Neplasm metastasis.

Publication types

  • Case Reports